News	Drug Formulary	Safety Net	Resources
	Drug Formulary Categories and Charges Search HA Drug Formulary Self-financed Drugs Available for Purchase by Patients at HA Pharmacy How we evaluate new drugs Governance Drug Management Committee Drug Advisory Committee Drug Formulary Committee Drug & Therapeutics Committee Drug Selection Committee Expert Panel Medication Safety Committee	Samaritan Fund Community Care Fund	Drug Education HA Drug Formulary Management Manual Frequently Asked Questions Useful Links

DAC Meeting Outcome

DAC Meeting Outcome - Apr 2023

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection¹
1	Alpelisib / Fulvestrant	Piqray	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
2	Atezolizumab	Tecentriq	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
3	Brolucizumab	Beovu	Eye	Rejected	Alternative(s) available in HADF with comparable benefits
4	Burosumab	Crysvita	Endocrine system	Approved
5	Busulfan	Busulfex	Malignant disease and immunosuppression	Approved
6	Capmatinib	Tabrecta	Malignant disease and immunosuppression	Rejected	Insufficient evidence of long-term clinical outcome benefits
7	Daratumumab / Bortezomib	Darzalex	Malignant disease and immunosuppression	Approved
8	Dupilumab	Dupixent	Ear, nose, and oropharynx	Pending	Pending further information
9	Empagliflozin	Jardiance	Endocrine system	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
10	Esketamine	Spravato	Central nervous system	Approved
11	Faricimab	Vabysmo	Eye	Pending	Pending further information
12	Finerenone	Kerendia	Cardiovascular system	Pending	Pending further information
13	Isatuximab / Pomalidomide	Sarclisa	Malignant disease and immunosuppression	Approved
14	L-arginine hydrochloride L-lysine hydrochloride	LysaKare	Nutrition and blood	Rejected	The justification of the treatment’s cost in relation to its benefits is insufficient
15	Latanoprostene Bunod	Vyzulta	Eye	Approved
16	Lutetium oxodotreotide	Lutathera	Radiopharmaceuticals	Rejected	The justification of the treatment’s cost in relation to its benefits is insufficient
17	Mepolizumab	Nucala	Malignant disease and immunosuppression	Approved
18	Nivolumab	Opdivo	Malignant disease and immunosuppression	Rejected	Insufficient evidence of long-term clinical outcome benefits
19	Nonacog alfa	BeneFIX	Cardiovascular system	Approved
20	Olaparib / Bevacizumab	Lynparza	Malignant disease and immunosuppression	Rejected	Insufficient evidence of long-term clinical outcome benefits
21	Onasemnogene abeparvovec	Zolgensma	Musculoskeletal and joint disease	Pending	Pending further information
22	Osimertinib	Tagrisso	Malignant disease and immunosuppression	Rejected	Insufficient evidence of long-term clinical outcome benefits
23	Oxycodone / Naloxone	Targin	Central nervous system	Pending	Pending further information
24	Polatuzumab vedotin / Rituximab	Polivy	Malignant disease and immunosuppression	Approved
25	Ravulizumab	Ultomiris	Nutrition and blood	Approved
26	Ripretinib	Qinlock	Malignant disease and immunosuppression	Pending	Pending further information
27	Ruxolitinib	Jakavi	Malignant disease and immunosuppression	Pending	Pending further information
28	Siltuximab	Sylvant	Malignant disease and immunosuppression	Approved
29	Tolvaptan	Jinarc	Endocrine system	Approved
30	Trastuzumab Deruxtecan	Enhertu	Malignant disease and immunosuppression	Pending	Pending further information
31	Trifluridine/tipiracil	Lonsurf	Malignant disease and immunosuppression	Approved
32	Tucatinib / Trastuzumab	Tukysa	Malignant disease and immunosuppression	Pending	Pending further information
33	Upadacitinib	Rinvoq	Skin	Approved